Results 221 to 230 of about 50,269 (316)

Angiogenesis as a Therapeutic Target of (Poly)phenols: Tackling Cancer and Vascular‐Related Complications

Molecular Nutrition &Food Research, Volume 69, Issue 15, August 2025.
(Poly)phenols constitute a source of natural therapeutic molecules capable of targeting angiogenesis in different scenarios. This review summarizes the current evidence of the role of (poly)phenols in modulating angiogenesis. The reader can find a compilation of preclinical and human investigations describing pro‐ and anti‐angiogenic effects of these ...
María Ángeles Ávila‐Gálvez, Antonio Vico‐Padilla, Claus Schneider, Juan Carlos Espín, Antonio González‐Sarrías, Juan Antonio Giménez‐Bastida   +5 more
wiley   +1 more source

Abdominal wall hernia is a frequent complication of polycystic liver disease and associated with hepatomegaly. [PDF]

Liver Int, 2022
Barten TRM, Bökkerink RMP, Venderink W, Gevers TJG, Ten Broek RPG, Drenth JPH.   +5 more
europepmc   +1 more source

Structural and Functional Analyses of Liver Cysts from the BALB/c-cpk Mouse Model of Polycystic Kidney Disease

, 2008
Monalisa Muchatuta, Vincent H. Gattone, Frank A. Witzmann, Bonnie L. Blazer‐Yost   +3 more
openalex   +2 more sources

Fenestration Treatment for Polycystic Liver Disease Improved Quality of Life [PDF]

, 2013
Tonguç Utku Yılmaz, Hakan Sözen Doç, Koray Kılıç, Gonca Erbaş Doç, Aydın Dalgıç   +4 more
openalex   +1 more source

Oral MIB‐626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID‐19 and Acute Kidney Injury: A Randomized Controlled Trial

FASEB BioAdvances, Volume 7, Issue 8, August 2025.
This randomized, placebo‐controlled trial assessed the effects of NAD augmentation by administration of oral β Nicotinamide Mononucleotide (β NMN) 1.0 g twice daily or placebo for 14 days in adult patients hospitalized with COVID‐19 and acute kidney injury on blood NAD, plasma levels of NAD metabolites, biomarkers of acute kidney injury, inflammation ...
Karol M. Pencina, David E. Leaf, Rodrigo J. Valderrabano, Sushrut S. Waikar, Tapan S. Mehta, Yili Valentine Shang, Nancy K. Latham, Tejossy John, Elena Volpi, Dahlene Fusco, Yusnie Memish‐Beleva, Shobana Krishnamurthy, Siva Lavu, Salma Karmi, David J. Livingston, Shalender Bhasin   +15 more
wiley   +1 more source

Retraction: Isolated Polycystic Liver Disease: A Rare Genetic Disorder. [PDF]

Cureus
Aldabbab HY, Hakeem MA, Alanazi FM, Asiri MA, Al Hani MF, Alshareef RI, Alkahtani AR, Alfadhli RF, Alharbi LY, Jan AA, Alraddadi MM, Alshammari M.   +11 more
europepmc   +1 more source

Treatment of polycystic liver disease with resection-fenestration and a new classification

, 2008
Tuanjie Li, Haibin Zhang, LU Junhua, Jun Zhao, Ning Yang, Guang-Shun Yang   +5 more
openalex   +1 more source

Treated mothers, troubled hearts: cardiovascular trade‐offs of metformin use in pregnancy

The Journal of Physiology, EarlyView.
Clare M. Reynolds
wiley   +1 more source

Gut Microbiota‐Derived Acetate Ameliorates Endometriosis via JAK1/STAT3‐Mediated M1 Macrophage Polarisation

Microbial Biotechnology, Volume 18, Issue 8, August 2025.
This study first reveals acetate as a key gut microbiota metabolite to ameliorate endometriosis (EMs) via JAK1/STAT3‐mediated M1 macrophage polarisation, confirming healthy donor faecal microbiota transplantation (FMT) improves EMs by reshaping microbiota, enhancing acetate, strengthening intestinal barriers and providing a new therapeutic paradigm ...
Yunyun Xu, Yichen Zhu, Xiaoyun Wu, Wan Peng, Yanying Zhong, Yujie Cai, Wenjing Chen, Lu Liu, BuZhen Tan, Tingtao Chen   +9 more
wiley   +1 more source

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use. [PDF]

PLoS One, 2022
Mizuno H, Sekine A, Suwabe T, Ikuma D, Yamanouchi M, Hasegawa E, Sawa N, Ubara Y, Hoshino J.   +8 more
europepmc   +1 more source